跳至主要内容
临床试验/NCT02985346
NCT02985346Unknown早期 1 期

Sun Yat-sen Memorial Hospital

Sun Yat-sen University0 个研究点目标入组 100 人开始时间: 2017年1月1日最近更新:
适应症

试验速览

阶段
早期 1 期
发起方
入组人数
100
主要终点
Complete remission

研究概览

简要总结

Pulmonary hemosiderosis (PH) is a pulmonary hemosiderin deposition which caused by alveolar capillary hemorrhage. PH is easy to recurrent and can lead to pulmonary fibrosis and insufficiency if the disease was poor controlled. Steroid is the most common drug that was administered in acute phase of the disease. However, considered the side-effects, steroid is not suitable for long-time maintenance. Therefore, it is necessary to explore a new therapy. Bone marrow mesenchymal stem cells (BMSC) are a kind of adult stem cells with high self-renewal and multi-directional differentiation potential in bone marrow. It has become a hot topic in immunosuppressive and tissue repair therapy in recent years. To date, homing, colonization and differentiation of BMSCs in the lung have been observed in animal models of pulmonary hypertension, radiation pneumonitis and pulmonary fibrosis. It had been reported that BMSC transplantation in acute lung injury in mice, inflammation of lung injury can significantly improve. The aim of this study is to explore the effect of BMSC on PH and its mechanism, and to explore a new way to promote the repair of IPH. It is expected to improve the status of IPH therapy in children, especially improve the prognosis of refractory PH.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Month 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients diagnosed with Pulmonary hemosiderosis at an age less than 18 years.

排除标准

  • Patients who cannot finish the established causes or die during the causes.

结局指标

主要结局

Complete remission

时间窗: 3-6 months

次要结局

未报告次要终点

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Weiping Tan

Sun Yat-sen Memorial Hospital

Sun Yat-sen University

相似试验